Health Care

Quest Diagnostics CEO sells 10,000 shares in a routine 10‑b5‑1 plan – no market shock, steady fundamentals and predictable liquidity strategy.

Hyperion DeFi insider buys boost confidence as Phase II results show promising visual‑acuity gains for nAMD therapy, hinting at future FDA approval and market impact.

Hecht Beth’s steady insider sales at Xeris Biopharma signal a strategic realignment and possible undervaluation—watch how pipeline prospects may drive a rally or decline.

Explore GRAIL’s insider trades, Galleri’s market rollout, and the biopharma landscape—insights into strategy, pricing, and investor confidence.

CRISPR Therapeutics insider RSU purchase signals long‑term confidence in gene‑editing platform, sparking a stock rally and heightened investor buzz.

Insider sales at Vir Biotechnology show routine portfolio moves, not a warning—see how recent trades and pipeline prospects influence investor sentiment and market value.

Halozyme insider sale analysis: a routine portfolio move amid steady bispecific antibody growth and mid‑cap stability.

Rona Anhalt’s steady RSU‑to‑cash trades show Certara’s HR chief is invested in long‑term value, boosting investor confidence in the company’s biosimulation‑driven growth.

Centene insider sale: Carson Michael A’s 604 phantom‑stock units reveal executive confidence in Medicaid growth and upcoming vesting rewards for investors.

HealthEquity insider sale: EVP Michael Fiore sells 3,142 shares at $95, capturing a premium. Investor insight on liquidity, confidence, and the company’s value‑based health‑tech strategy.